Top-News
Krebsforschung USA

OncoSec Medical News

Aktie
WKN:  A3D1RU ISIN:  US68234L4059 US-Symbol:  ONCSQ
0,0003 $
+0,0002 $
+200,00%
09.05.24 15:44:15
Handeln Depot/Watchlist
Aktienanzahl *
1,78 Mio.
Marktkapitalisierung *
164 €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 09.11.2022

OncoSec Medical News

18.05.23 - PR Newswire
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
16.05.23 - PR Newswire
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
16.05.23 - PR Newswire
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program PR Newswire
27.04.23 - PR Newswire
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ...
11.04.23 - PR Newswire
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
10.04.23 - PR Newswire
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces $2 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
03.04.23 - PR Newswire
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma ...
02.03.23 - PR Newswire
Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's?
Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's? PR Newswire
01.03.23 - PR Newswire
Thinking about buying stock in Reata Pharmaceuticals, OncoSec Medical, Lucira Health, B&G Foods, or Payoneer Global?
Thinking about buying stock in Reata Pharmaceuticals, OncoSec Medical, Lucira Health, B&G Foods, or Payoneer Global? PR Newswire
05.12.22 - PR Newswire
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 PR Newswire
30.11.22 - PR Newswire
OncoSec Announces Pricing of $3.5 Million Public Offering
OncoSec Announces Pricing of $3.5 Million Public Offering PR Newswire
22.11.22 - PR Newswire
Thinking about buying stock in Abercrombie & Fitch, GoldMining, NRX Pharmaceuticals, Vipshop Holdings, or OncoSec Medical?
Thinking about buying stock in Abercrombie & Fitch, GoldMining, NRX Pharmaceuticals, Vipshop Holdings, or OncoSec Medical? PR Newswire
15.11.22 - PR Newswire
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma PR Newswire
11.11.22 - PR Newswire
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma ...
08.11.22 - PR Newswire
OncoSec Announces Reverse Stock Split
OncoSec Announces Reverse Stock Split PR Newswire
04.10.22 - PR Newswire
OncoSec Announces Pipeline Prioritization and Workforce Reduction
OncoSec Announces Pipeline Prioritization and Workforce Reduction PR Newswire
20.03.20 - ACCESSWIRE
OncoSec Medical Incorporated to Present at the New York City based Investor Summit on March 25th-26th
NEW YORK, NY / ACCESSWIRE / March 20, 2020 / OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-​stage intratumoral cancer ...
09.06.16 - PR Newswire
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 PR Newswire
25.03.13 - PR Newswire
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients 45 percent of Treated Lesions Demonstrated a Durable ...
18.03.13 - PR Newswire
OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York PR Newswire

Newssuche

Videos

29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »